Details

Autor(en) / Beteiligte

• Lavoue, V.
• Huchon, C.
• Akladios, C.
• Alfonsi, P.
• Bakrin, N.
• Ballester, M.
• Bendifallah, S.
• Bolze, P.A.
• Bonnet, F.
• Bourgin, C.
• Chabbert-Buffet, N.
• Collinet, P.
• Courbiere, B.
• De la motte rouge, T.
• Devouassoux-Shisheboran, M.
• Falandry, C.
• Ferron, G.
• Fournier, L.
• Gladieff, L.
• Golfier, F
• Gouy, S.
• Guyon, F.
• Lambaudie, E
• Leary, A.
• Lecuru, F.
• Lefrere-Belda, M.A.
• Leblanc, E.
• Lemoine, A
• Narducci, F.
• Ouldamer, L.
• Pautier, P.
• Planchamp, F.
• Pouget, N.
• Ray-Coquard, I.
• Rousset-Jablonski, C.
• Senechal-Davin, C.
• Touboul, C.
• Thomassin-Naggara, I.
• Uzan, C.
• You, B.
• Daraï, E.

Titel

Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)

Ist Teil von

• Journal of gynecology obstetrics and human reproduction, 2019-06, Vol.48 (6), p.379-386

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).